Association of fluconazole area under the concentration-time curve/MIC and dose/MIC ratios with mortality in nonneutropenic patients with candidemia.
about
Therapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspectiveFluconazole dosing for the prevention or treatment of invasive candidiasis in young infantsPharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: Data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients Study.Evaluation by data mining techniques of fluconazole breakpoints established by the Clinical and Laboratory Standards Institute (CLSI) and comparison with those of the European Committee on Antimicrobial Susceptibility Testing (EUCAST)An investigation of the inhibitory effects of dendrosomal nanocurcumin on Candida albicans and systemic candidiasis in BALB/c mice.Worrisome trends in incidence and mortality of candidemia in intensive care units (Paris area, 2002-2010)How much European prescribing physicians know about invasive fungal infections management?Population pharmacokinetics of fluconazole in critically ill patients receiving continuous venovenous hemodiafiltration: using Monte Carlo simulations to predict doses for specified pharmacodynamic targets.Antifungal pharmacokinetics and pharmacodynamicsFluconazole population pharmacokinetics and dosing for prevention and treatment of invasive Candidiasis in children supported with extracorporeal membrane oxygenation.Epidemiology and antifungal resistance in invasive candidiasis.Impact of prior inappropriate fluconazole dosing on isolation of fluconazole-nonsusceptible Candida species in hospitalized patients with candidemia.Correlation of the MIC and dose/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidemiaOptimizing Echinocandin dosing and susceptibility breakpoint determination via in vivo pharmacodynamic evaluation against Candida glabrata with and without fks mutations.Posaconazole pharmacodynamic target determination against wild-type and Cyp51 mutant isolates of Aspergillus fumigatus in an in vivo model of invasive pulmonary aspergillosisPopulation pharmacokinetic analysis of fluconazole to predict therapeutic outcome in burn patients with Candida infectionFluconazole versus an echinocandin for Candida glabrata fungaemia: a retrospective cohort study.Nosocomial fungal infections: epidemiology, diagnosis, and treatment.In Vitro Susceptibility and Trailing Growth Effect of Clinical Isolates of Candida Species to Azole Drugs.Association of fluconazole pharmacodynamics with mortality in patients with candidemiaComparative efficacies of Zataria multiflora essential oil and itraconazole against disseminated Candida albicans infection in BALB/c mice.Susceptible, intermediate, and resistant - the intensity of antibiotic action.Isavuconazole pharmacodynamic target determination for Candida species in an in vivo murine disseminated candidiasis model.Antifungal therapeutic drug monitoring: established and emerging indications.Effective concentration-based serum pharmacodynamics for antifungal azoles in a murine model of disseminated Candida albicans infection.Determinants of mortality in non-neutropenic ICU patients with candidaemiaSafety of triazole antifungal drugs in patients with cancer.Opportunistic invasive fungal infections: diagnosis & clinical management.The risk and clinical outcome of candidemia depending on underlying malignancy.Diagnosis and therapy of Candida infections: joint recommendations of the German Speaking Mycological Society and the Paul-Ehrlich-Society for Chemotherapy.Current concepts in antifungal pharmacology.Pharmacokinetic evaluation of fluconazole in critically ill patients.Opportunistic fungal infections in the Asia-Pacific region.The evolving role of antifungal susceptibility testing.Candida glabrata--unique features and challenges in the clinical management of invasive infections.Dosing of antifungal agents in obese people.Therapeutic drug monitoring of anti-infective agents in critically ill patients.The Etest Performed Directly on Blood Culture Bottles Is a Reliable Tool for Detection of Fluconazole-Resistant Candida albicans Isolates.To test or not to test: a cost minimization analysis of susceptibility testing for patients with documented Candida glabrata fungemias.Support for the EUCAST and revised CLSI fluconazole clinical breakpoints by Sensititre® YeastOne® for Candida albicans: a prospective observational cohort study.
P2860
Q27009221-4AFD06DE-3D78-43A1-98A1-96215012C365Q30435365-7CFD2B57-A2C1-4C37-AD6C-AECCADC5F065Q30936281-0D1F93C7-3308-40B6-A30E-FC31CBA37A00Q33528384-72AD98BA-5F50-4CAC-9779-475D5FF50632Q33851306-9979F03A-F7FE-4CE4-B65C-3F13000638E2Q34100598-2DFD5526-BE64-4715-9B08-67289AE6BC0DQ35131938-7D7C5818-E512-4BE6-B5E3-3D68497FFAD1Q35598414-A2B32142-AFCA-4684-82CD-0B2C6D274D14Q35663841-81D88BF6-0B2C-42E5-9DA3-8B34D1AA799CQ35746253-6EA9F34F-54A0-4D69-8BE9-A306B0E3C8CCQ35959495-C6CE3984-8C7E-406B-AE05-353A75918BF8Q36018860-594F0E9A-6017-4533-AE93-74FFA7DC204EQ36094974-25DF5640-3AAD-458D-AF58-AA75DD08B7C9Q36364100-E7328D05-536A-4544-A779-78AD534EB0D4Q36505539-8BA86F6E-9410-4E66-B36C-6A903A040697Q36558341-D4954AA9-BE55-4DFB-B3A8-973670062908Q36675142-5298A1F0-1D2E-41E7-80D6-179755F07E20Q36825717-A1A4D244-7B8E-4230-8714-65BE7051F6A7Q36828123-EDDDEFA7-2EB2-4585-8874-6B60977DB5FBQ36870712-5A6E8D2C-60E1-41E9-B3D6-8BD429E1EABFQ37159342-51AEF2CB-C8B2-4CDE-8E41-7550161AFA2DQ37239104-521C7DAE-DAD6-4FDA-A88C-633F0E32541AQ37263435-575E07A6-C1C3-4880-963F-FA0A6E90492FQ37310029-78551ECC-21A5-4500-8577-489E61923226Q37356974-140189CD-0FD1-434F-A6D7-21A4D34EA66EQ37360312-001B0D88-D002-4E98-B525-45395E8EFEBFQ37662650-BF57A5D4-D2F5-4E03-BC20-6F036381CDE1Q37726198-4186FB49-884A-402F-8435-EDC9830DA006Q37742252-9B4859C4-776B-463D-A6FE-21E7FB86D6D9Q37889382-3FCD7024-7565-41EC-895D-905A50DCD529Q37908856-38C2139B-82E9-4451-9F23-F2DE118C2614Q37924819-A49E81D1-A3E1-46D1-A088-C9CDF6EA969CQ37929788-CB485359-77CA-44F9-B83F-0B3BE3661431Q38095809-E2D0635A-CEE1-4B49-937D-5870D8D51562Q38553440-717FBF18-8D6D-48E7-AA87-A82CE586E399Q38660761-963C68A3-D205-4C05-BA13-0A92E89AE040Q38790740-D7D2E957-1477-4FA6-856D-36ACE385F4A4Q40220987-71632E95-39D2-4397-B66C-75C2AA32EEA3Q41971254-1D81EAF3-487E-4970-A874-10D1A9EBCAC3Q42217003-5CB026E2-41E9-4F8F-8B23-47A0766D5450
P2860
Association of fluconazole area under the concentration-time curve/MIC and dose/MIC ratios with mortality in nonneutropenic patients with candidemia.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Association of fluconazole are ...... enic patients with candidemia.
@ast
Association of fluconazole are ...... enic patients with candidemia.
@en
type
label
Association of fluconazole are ...... enic patients with candidemia.
@ast
Association of fluconazole are ...... enic patients with candidemia.
@en
prefLabel
Association of fluconazole are ...... enic patients with candidemia.
@ast
Association of fluconazole are ...... enic patients with candidemia.
@en
P2093
P2860
P356
P1476
Association of fluconazole are ...... enic patients with candidemia.
@en
P2093
Kevin W Garey
Manjunath P Pai
Robin S Turpin
P2860
P356
10.1128/AAC.00474-06
P407
P577
2006-11-13T00:00:00Z